Keywords: biotransplant, bti-322, mode, action, characterization, researchers, described

BioTransplant's BTI-322: mode of action characterization

Article | 27 November 1995

- BioTransplant researchers have described the mode of action of BTI-322, the firm's anti-CD2 monoclonal antibody for preventing transplant rejection. They ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in